Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The study investigates the changes in miRNAs expression between healthy controls (HCs) and naive MS patients in peripheral blood mononuclear cells (PBMCs) and explores the immunological effect of OCRE aside from direct B cell depletion

Next Previous
Trial Profile

The study investigates the changes in miRNAs expression between healthy controls (HCs) and naive MS patients in peripheral blood mononuclear cells (PBMCs) and explores the immunological effect of OCRE aside from direct B cell depletion

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics

Most Recent Events

  • 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
  • 07 Apr 2022 New trial record
  • 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top